世界のHER2陰性乳がん治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2802 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、HER2陰性乳がん治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、外科、放射線、ホルモン療法/内分泌療法）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・HER2陰性乳がん治療の市場動向 ・企業の競争状況、市場シェア ・HER2陰性乳がん治療の種類別市場規模（化学療法、外科、放射線、ホルモン療法/内分泌療法） ・HER2陰性乳がん治療の用途別市場規模（病院、クリニック） ・HER2陰性乳がん治療の北米市場規模2016-2027（アメリカ、カナダ） ・HER2陰性乳がん治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・HER2陰性乳がん治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・HER2陰性乳がん治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・HER2陰性乳がん治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca、Bristol-Myers Squibb、Eli Lilly、Pfizer、Novartis、Pfizer、GlaxoSmithKline、Novartis、Merck、Eli Lilly） ・結論

HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.

Market Analysis and Insights: Global HER2-negative breast cancer Treatment Market
The global HER2-negative breast cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global HER2-negative breast cancer Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global HER2-negative breast cancer Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global HER2-negative breast cancer Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global HER2-negative breast cancer Treatment market.

Global HER2-negative breast cancer Treatment Scope and Market Size
HER2-negative breast cancer Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global HER2-negative breast cancer Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chemotherapy
Surgery
Radiation
Hormonal therapy/endocrine therapy

Segment by Application
Hosptial
Clinic

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Pfizer
Novartis
Pfizer
GlaxoSmithKline
Novartis
Merck

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HER2-negative breast cancer Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Surgery
1.2.4 Radiation
1.2.5 Hormonal therapy/endocrine therapy
1.3 Market by Application
1.3.1 Global HER2-negative breast cancer Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hosptial
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global HER2-negative breast cancer Treatment Market Perspective (2016-2027)
2.2 HER2-negative breast cancer Treatment Growth Trends by Regions
2.2.1 HER2-negative breast cancer Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 HER2-negative breast cancer Treatment Historic Market Share by Regions (2016-2021)
2.2.3 HER2-negative breast cancer Treatment Forecasted Market Size by Regions (2022-2027)
2.3 HER2-negative breast cancer Treatment Industry Dynamic
2.3.1 HER2-negative breast cancer Treatment Market Trends
2.3.2 HER2-negative breast cancer Treatment Market Drivers
2.3.3 HER2-negative breast cancer Treatment Market Challenges
2.3.4 HER2-negative breast cancer Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top HER2-negative breast cancer Treatment Players by Revenue
3.1.1 Global Top HER2-negative breast cancer Treatment Players by Revenue (2016-2021)
3.1.2 Global HER2-negative breast cancer Treatment Revenue Market Share by Players (2016-2021)
3.2 Global HER2-negative breast cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by HER2-negative breast cancer Treatment Revenue
3.4 Global HER2-negative breast cancer Treatment Market Concentration Ratio
3.4.1 Global HER2-negative breast cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HER2-negative breast cancer Treatment Revenue in 2020
3.5 HER2-negative breast cancer Treatment Key Players Head office and Area Served
3.6 Key Players HER2-negative breast cancer Treatment Product Solution and Service
3.7 Date of Enter into HER2-negative breast cancer Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 HER2-negative breast cancer Treatment Breakdown Data by Type
4.1 Global HER2-negative breast cancer Treatment Historic Market Size by Type (2016-2021)
4.2 Global HER2-negative breast cancer Treatment Forecasted Market Size by Type (2022-2027)

5 HER2-negative breast cancer Treatment Breakdown Data by Application
5.1 Global HER2-negative breast cancer Treatment Historic Market Size by Application (2016-2021)
5.2 Global HER2-negative breast cancer Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America HER2-negative breast cancer Treatment Market Size (2016-2027)
6.2 North America HER2-negative breast cancer Treatment Market Size by Type
6.2.1 North America HER2-negative breast cancer Treatment Market Size by Type (2016-2021)
6.2.2 North America HER2-negative breast cancer Treatment Market Size by Type (2022-2027)
6.2.3 North America HER2-negative breast cancer Treatment Market Size by Type (2016-2027)
6.3 North America HER2-negative breast cancer Treatment Market Size by Application
6.3.1 North America HER2-negative breast cancer Treatment Market Size by Application (2016-2021)
6.3.2 North America HER2-negative breast cancer Treatment Market Size by Application (2022-2027)
6.3.3 North America HER2-negative breast cancer Treatment Market Size by Application (2016-2027)
6.4 North America HER2-negative breast cancer Treatment Market Size by Country
6.4.1 North America HER2-negative breast cancer Treatment Market Size by Country (2016-2021)
6.4.2 North America HER2-negative breast cancer Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe HER2-negative breast cancer Treatment Market Size (2016-2027)
7.2 Europe HER2-negative breast cancer Treatment Market Size by Type
7.2.1 Europe HER2-negative breast cancer Treatment Market Size by Type (2016-2021)
7.2.2 Europe HER2-negative breast cancer Treatment Market Size by Type (2022-2027)
7.2.3 Europe HER2-negative breast cancer Treatment Market Size by Type (2016-2027)
7.3 Europe HER2-negative breast cancer Treatment Market Size by Application
7.3.1 Europe HER2-negative breast cancer Treatment Market Size by Application (2016-2021)
7.3.2 Europe HER2-negative breast cancer Treatment Market Size by Application (2022-2027)
7.3.3 Europe HER2-negative breast cancer Treatment Market Size by Application (2016-2027)
7.4 Europe HER2-negative breast cancer Treatment Market Size by Country
7.4.1 Europe HER2-negative breast cancer Treatment Market Size by Country (2016-2021)
7.4.2 Europe HER2-negative breast cancer Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific HER2-negative breast cancer Treatment Market Size (2016-2027)
8.2 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Type
8.2.1 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Application
8.3.1 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Region
8.4.1 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific HER2-negative breast cancer Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America HER2-negative breast cancer Treatment Market Size (2016-2027)
9.2 Latin America HER2-negative breast cancer Treatment Market Size by Type
9.2.1 Latin America HER2-negative breast cancer Treatment Market Size by Type (2016-2021)
9.2.2 Latin America HER2-negative breast cancer Treatment Market Size by Type (2022-2027)
9.2.3 Latin America HER2-negative breast cancer Treatment Market Size by Type (2016-2027)
9.3 Latin America HER2-negative breast cancer Treatment Market Size by Application
9.3.1 Latin America HER2-negative breast cancer Treatment Market Size by Application (2016-2021)
9.3.2 Latin America HER2-negative breast cancer Treatment Market Size by Application (2022-2027)
9.3.3 Latin America HER2-negative breast cancer Treatment Market Size by Application (2016-2027)
9.4 Latin America HER2-negative breast cancer Treatment Market Size by Country
9.4.1 Latin America HER2-negative breast cancer Treatment Market Size by Country (2016-2021)
9.4.2 Latin America HER2-negative breast cancer Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa HER2-negative breast cancer Treatment Market Size (2016-2027)
10.2 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Type
10.2.1 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Application
10.3.1 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Country
10.4.1 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa HER2-negative breast cancer Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca HER2-negative breast cancer Treatment Introduction
11.1.4 AstraZeneca Revenue in HER2-negative breast cancer Treatment Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb HER2-negative breast cancer Treatment Introduction
11.2.4 Bristol-Myers Squibb Revenue in HER2-negative breast cancer Treatment Business (2016-2021)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly HER2-negative breast cancer Treatment Introduction
11.3.4 Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2016-2021)
11.3.5 Eli Lilly Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer HER2-negative breast cancer Treatment Introduction
11.4.4 Pfizer Revenue in HER2-negative breast cancer Treatment Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis HER2-negative breast cancer Treatment Introduction
11.5.4 Novartis Revenue in HER2-negative breast cancer Treatment Business (2016-2021)
11.5.5 Novartis Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer HER2-negative breast cancer Treatment Introduction
11.6.4 Pfizer Revenue in HER2-negative breast cancer Treatment Business (2016-2021)
11.6.5 Pfizer Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Details
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline HER2-negative breast cancer Treatment Introduction
11.7.4 GlaxoSmithKline Revenue in HER2-negative breast cancer Treatment Business (2016-2021)
11.7.5 GlaxoSmithKline Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis HER2-negative breast cancer Treatment Introduction
11.8.4 Novartis Revenue in HER2-negative breast cancer Treatment Business (2016-2021)
11.8.5 Novartis Recent Development
11.9 Merck
11.9.1 Merck Company Details
11.9.2 Merck Business Overview
11.9.3 Merck HER2-negative breast cancer Treatment Introduction
11.9.4 Merck Revenue in HER2-negative breast cancer Treatment Business (2016-2021)
11.9.5 Merck Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Details
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly HER2-negative breast cancer Treatment Introduction
11.10.4 Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2016-2021)
11.10.5 Eli Lilly Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global HER2-negative breast cancer Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Surgery
Table 4. Key Players of Radiation
Table 5. Key Players of Hormonal therapy/endocrine therapy
Table 6. Global HER2-negative breast cancer Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global HER2-negative breast cancer Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global HER2-negative breast cancer Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global HER2-negative breast cancer Treatment Market Share by Regions (2016-2021)
Table 10. Global HER2-negative breast cancer Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global HER2-negative breast cancer Treatment Market Share by Regions (2022-2027)
Table 12. HER2-negative breast cancer Treatment Market Trends
Table 13. HER2-negative breast cancer Treatment Market Drivers
Table 14. HER2-negative breast cancer Treatment Market Challenges
Table 15. HER2-negative breast cancer Treatment Market Restraints
Table 16. Global HER2-negative breast cancer Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global HER2-negative breast cancer Treatment Market Share by Players (2016-2021)
Table 18. Global Top HER2-negative breast cancer Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER2-negative breast cancer Treatment as of 2020)
Table 19. Ranking of Global Top HER2-negative breast cancer Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by HER2-negative breast cancer Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players HER2-negative breast cancer Treatment Product Solution and Service
Table 23. Date of Enter into HER2-negative breast cancer Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global HER2-negative breast cancer Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global HER2-negative breast cancer Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global HER2-negative breast cancer Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global HER2-negative breast cancer Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global HER2-negative breast cancer Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global HER2-negative breast cancer Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global HER2-negative breast cancer Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global HER2-negative breast cancer Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America HER2-negative breast cancer Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America HER2-negative breast cancer Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America HER2-negative breast cancer Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America HER2-negative breast cancer Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America HER2-negative breast cancer Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America HER2-negative breast cancer Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe HER2-negative breast cancer Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe HER2-negative breast cancer Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe HER2-negative breast cancer Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe HER2-negative breast cancer Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe HER2-negative breast cancer Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe HER2-negative breast cancer Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific HER2-negative breast cancer Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific HER2-negative breast cancer Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific HER2-negative breast cancer Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific HER2-negative breast cancer Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific HER2-negative breast cancer Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific HER2-negative breast cancer Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America HER2-negative breast cancer Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America HER2-negative breast cancer Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America HER2-negative breast cancer Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America HER2-negative breast cancer Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America HER2-negative breast cancer Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America HER2-negative breast cancer Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa HER2-negative breast cancer Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa HER2-negative breast cancer Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa HER2-negative breast cancer Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa HER2-negative breast cancer Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa HER2-negative breast cancer Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa HER2-negative breast cancer Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. AstraZeneca Company Details
Table 64. AstraZeneca Business Overview
Table 65. AstraZeneca HER2-negative breast cancer Treatment Product
Table 66. AstraZeneca Revenue in HER2-negative breast cancer Treatment Business (2016-2021) & (US$ Million)
Table 67. AstraZeneca Recent Development
Table 68. Bristol-Myers Squibb Company Details
Table 69. Bristol-Myers Squibb Business Overview
Table 70. Bristol-Myers Squibb HER2-negative breast cancer Treatment Product
Table 71. Bristol-Myers Squibb Revenue in HER2-negative breast cancer Treatment Business (2016-2021) & (US$ Million)
Table 72. Bristol-Myers Squibb Recent Development
Table 73. Eli Lilly Company Details
Table 74. Eli Lilly Business Overview
Table 75. Eli Lilly HER2-negative breast cancer Treatment Product
Table 76. Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2016-2021) & (US$ Million)
Table 77. Eli Lilly Recent Development
Table 78. Pfizer Company Details
Table 79. Pfizer Business Overview
Table 80. Pfizer HER2-negative breast cancer Treatment Product
Table 81. Pfizer Revenue in HER2-negative breast cancer Treatment Business (2016-2021) & (US$ Million)
Table 82. Pfizer Recent Development
Table 83. Novartis Company Details
Table 84. Novartis Business Overview
Table 85. Novartis HER2-negative breast cancer Treatment Product
Table 86. Novartis Revenue in HER2-negative breast cancer Treatment Business (2016-2021) & (US$ Million)
Table 87. Novartis Recent Development
Table 88. Pfizer Company Details
Table 89. Pfizer Business Overview
Table 90. Pfizer HER2-negative breast cancer Treatment Product
Table 91. Pfizer Revenue in HER2-negative breast cancer Treatment Business (2016-2021) & (US$ Million)
Table 92. Pfizer Recent Development
Table 93. GlaxoSmithKline Company Details
Table 94. GlaxoSmithKline Business Overview
Table 95. GlaxoSmithKline HER2-negative breast cancer Treatment Product
Table 96. GlaxoSmithKline Revenue in HER2-negative breast cancer Treatment Business (2016-2021) & (US$ Million)
Table 97. GlaxoSmithKline Recent Development
Table 98. Novartis Company Details
Table 99. Novartis Business Overview
Table 100. Novartis Revenue in HER2-negative breast cancer Treatment Business (2016-2021) & (US$ Million)
Table 101. Novartis Recent Development
Table 102. Merck Company Details
Table 103. Merck Business Overview
Table 104. Merck HER2-negative breast cancer Treatment Product
Table 105. Merck Revenue in HER2-negative breast cancer Treatment Business (2016-2021) & (US$ Million)
Table 106. Merck Recent Development
Table 107. Eli Lilly Company Details
Table 108. Eli Lilly Business Overview
Table 109. Eli Lilly HER2-negative breast cancer Treatment Product
Table 110. Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2016-2021) & (US$ Million)
Table 111. Eli Lilly Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global HER2-negative breast cancer Treatment Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Surgery Features
Figure 4. Radiation Features
Figure 5. Hormonal therapy/endocrine therapy Features
Figure 6. Global HER2-negative breast cancer Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hosptial Case Studies
Figure 8. Clinic Case Studies
Figure 9. HER2-negative breast cancer Treatment Report Years Considered
Figure 10. Global HER2-negative breast cancer Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global HER2-negative breast cancer Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global HER2-negative breast cancer Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global HER2-negative breast cancer Treatment Market Share by Regions (2022-2027)
Figure 14. Global HER2-negative breast cancer Treatment Market Share by Players in 2020
Figure 15. Global Top HER2-negative breast cancer Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER2-negative breast cancer Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by HER2-negative breast cancer Treatment Revenue in 2020
Figure 17. Global HER2-negative breast cancer Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global HER2-negative breast cancer Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America HER2-negative breast cancer Treatment Market Share by Type (2016-2027)
Figure 21. North America HER2-negative breast cancer Treatment Market Share by Application (2016-2027)
Figure 22. North America HER2-negative breast cancer Treatment Market Share by Country (2016-2027)
Figure 23. United States HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe HER2-negative breast cancer Treatment Market Share by Type (2016-2027)
Figure 27. Europe HER2-negative breast cancer Treatment Market Share by Application (2016-2027)
Figure 28. Europe HER2-negative breast cancer Treatment Market Share by Country (2016-2027)
Figure 29. Germany HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific HER2-negative breast cancer Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific HER2-negative breast cancer Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific HER2-negative breast cancer Treatment Market Share by Region (2016-2027)
Figure 39. China HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America HER2-negative breast cancer Treatment Market Share by Type (2016-2027)
Figure 47. Latin America HER2-negative breast cancer Treatment Market Share by Application (2016-2027)
Figure 48. Latin America HER2-negative breast cancer Treatment Market Share by Country (2016-2027)
Figure 49. Mexico HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa HER2-negative breast cancer Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa HER2-negative breast cancer Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa HER2-negative breast cancer Treatment Market Share by Country (2016-2027)
Figure 55. Turkey HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE HER2-negative breast cancer Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. AstraZeneca Revenue Growth Rate in HER2-negative breast cancer Treatment Business (2016-2021)
Figure 59. Bristol-Myers Squibb Revenue Growth Rate in HER2-negative breast cancer Treatment Business (2016-2021)
Figure 60. Eli Lilly Revenue Growth Rate in HER2-negative breast cancer Treatment Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in HER2-negative breast cancer Treatment Business (2016-2021)
Figure 62. Novartis Revenue Growth Rate in HER2-negative breast cancer Treatment Business (2016-2021)
Figure 63. Pfizer Revenue Growth Rate in HER2-negative breast cancer Treatment Business (2016-2021)
Figure 64. GlaxoSmithKline Revenue Growth Rate in HER2-negative breast cancer Treatment Business (2016-2021)
Figure 65. Novartis Revenue Growth Rate in HER2-negative breast cancer Treatment Business (2016-2021)
Figure 66. Merck Revenue Growth Rate in HER2-negative breast cancer Treatment Business (2016-2021)
Figure 67. Eli Lilly Revenue Growth Rate in HER2-negative breast cancer Treatment Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---